Pteridine compounds for the treatment of psoriasis

Details Pteridine compounds for the treatment of psoriasis Pteridine compounds for the treatment of psoriasis

2004-07-15

2009-08-25

Habte, Kahsay T (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S048000

Reexamination Certificate

active

07579342

ABSTRACT:
The invention provides pteridine compounds of formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. Formula (I) in which A is a group of formula (a) or (b).

REFERENCES:
patent: 2924472 (1960-02-01), Bush
patent: 3318900 (1967-05-01), Janssen
patent: 3445120 (1969-05-01), Barr
patent: 4061459 (1977-12-01), Parmann
patent: 4126689 (1978-11-01), Sanczuk et al.
patent: 4188040 (1980-02-01), Wolf et al.
patent: 4213619 (1980-07-01), Arlt et al.
patent: 4234199 (1980-11-01), Moncaster et al.
patent: 4278677 (1981-07-01), Nedelec et al.
patent: 4410528 (1983-10-01), Teranishi et al.
patent: 4483544 (1984-11-01), Faerber et al.
patent: 4641858 (1987-02-01), Roux
patent: 5064207 (1991-11-01), Bengtsson
patent: 5169161 (1992-12-01), Jones
patent: 5297824 (1994-03-01), Imhof et al.
patent: 5521197 (1996-05-01), Audia
patent: 5599028 (1997-02-01), Neumann et al.
patent: 5826887 (1998-10-01), Neumann et al.
patent: 5988695 (1999-11-01), Corbett, Jr.
patent: 6142484 (2000-11-01), Valls, Jr.
patent: 6172067 (2001-01-01), Ito et al.
patent: 6248755 (2001-06-01), Chapman et al.
patent: 6329381 (2001-12-01), Kurimoto et al.
patent: 6407121 (2002-06-01), Nagamine et al.
patent: 6432981 (2002-08-01), Finke et al.
patent: 6790850 (2004-09-01), Willis et al.
patent: 6790854 (2004-09-01), Tsushima et al.
patent: 6875868 (2005-04-01), Bonnert et al.
patent: 6949643 (2005-09-01), Bonnert
patent: 6958343 (2005-10-01), Bonnert et al.
patent: 6958344 (2005-10-01), Bonnert et al.
patent: 7071193 (2006-07-01), Bonnert et al.
patent: 7169778 (2007-01-01), Denny et al.
patent: 2003/0032642 (2003-02-01), Bonnert et al.
patent: 2003/0107189 (2003-06-01), Bonnert et al.
patent: 2003/0119869 (2003-06-01), Burrows et al.
patent: 2004/0157853 (2004-08-01), Bonnert
patent: 2004/0224961 (2004-11-01), Willis et al.
patent: 2005/0171345 (2005-08-01), Bonnert et al.
patent: 2005/0234077 (2005-10-01), Bonnert et al.
patent: 2005/0272750 (2005-12-01), Brough et al.
patent: 2006/0100221 (2006-05-01), Bonnert
patent: 2006/0111569 (2006-05-01), Bonnert
patent: 2007/0142352 (2007-06-01), Bonnert et al.
patent: 2007/0282103 (2007-12-01), Butters et al.
patent: 2008/0306262 (2008-12-01), Bonnert
patent: 2331223 (1974-01-01), None
patent: 41 19 767 (1992-12-01), None
patent: 0 293 078 (1988-11-01), None
patent: 0 447 324 (1991-09-01), None
patent: 0 778 277 (1997-06-01), None
patent: 1 069 124 (2001-01-01), None
patent: 1 122 257 (2001-08-01), None
patent: 1 348 709 (2003-10-01), None
patent: 1009477 (1965-11-01), None
patent: 2359079 (2001-08-01), None
patent: 51-88994 (1993-07-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/30035 (1997-08-01), None
patent: WO 97/32856 (1997-09-01), None
patent: WO 97/40035 (1997-10-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 98/13354 (1998-04-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 99/02166 (1999-01-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/17773 (1999-04-01), None
patent: WO 99/36421 (1999-07-01), None
patent: WO 99/51608 (1999-10-01), None
patent: WO 00/08013 (2000-02-01), None
patent: WO 00/09511 (2000-02-01), None
patent: WO 00/38680 (2000-07-01), None
patent: WO 00/39129 (2000-07-01), None
patent: WO 00/40529 (2000-07-01), None
patent: WO 00/41669 (2000-07-01), None
patent: WO 00/45800 (2000-08-01), None
patent: WO 00/59502 (2000-10-01), None
patent: WO 00/76514 (2000-12-01), None
patent: WO 01/19825 (2001-03-01), None
patent: WO 01/25200 (2001-04-01), None
patent: WO 01/25242 (2001-04-01), None
patent: WO 01/58906 (2001-08-01), None
patent: WO 01/66525 (2001-09-01), None
patent: WO 01/92224 (2001-12-01), None
patent: WO 02/04434 (2002-01-01), None
patent: WO 02/08213 (2002-01-01), None
patent: WO 02/083693 (2002-10-01), None
patent: WO 03/024966 (2003-03-01), None
patent: WO 2004/026835 (2004-01-01), None
patent: WO 2004/026880 (2004-04-01), None
patent: WO 2005/033115 (2005-04-01), None
patent: WO 2005/056563 (2005-06-01), None
patent: WO 2005/082865 (2005-09-01), None
patent: WO 2006/064228 (2006-06-01), None
Patent Abstracts of Japan, abstract of JP-5-202047 A (Chugai Pharmaceut. Co. Ltd.) Aug. 10, 1993.
Manfred Ott et al., “Zur Synthese des 4-Amino-7-oxo-7, 8-dihydropteridin-N-8-beta-D-ribofuranosids—ein strukturanaloges Nucleosid des Adenosins”, vol. 107, Chem.Ber., 339-361 (1974).
Manfred Ott et al., “4-Amino-7, 8-Dihydro-2-(Methylmercapto)-8-beta, -D-ribofuranosylpteridin-7-One, Modified Fusion Reaction with Trimethylsilylated Pteridine Derivatives”, vol. 2, Nucl. Acid. Chem., 735-739 (1978).
Leonidas Kiriasis et al., “Synthesis and Properties of New Pteridine Nucleosides”, vol. 4, Dev. Biochem., 49-53 (1978).
Ahmed et al., “Novel synthesis of l-aryl-9-alkyl-2,3,3a,4,9,9a-hexahydro-lH-pyrrolo[2,3-b]quinoxalines by lithium aluminum hydride reduction of N-phenyl-l-benzimidazolylsuccinimides”, Caplus 79:92106 (1973).
Baly et al., “Biological Assays for C-X-C Chemokines”,Methods in Enzymology287:69-88 (1997).
Baxter et al., “Hit-to-Lead Studies: The Discovery of Potent, Orally Bioavailable Thiazolopyrimidine CXCR2 Receptor Antagonists”,Bioorg. Med. Chem. Lett. 16(4):90-963 (2006).
Berge et al., “Pharmaceutical Salts”,J. Pharm. Sci. 66:1-19 (1977).
Bodor et al., “Chemical Approaches to Drug Delivery”, in:Encyclopedia of Controlled Drug Delivery(1999 ed.), pp. 285-298.
Caplus, Accession No. 2000:76301, Document No. 132:98128, “Antiinflammatory and analgesic capsules containing betamethasone, vitamin B6, dihydrochlorothiazide and triamterene”.
Chemcats, Accession No. 2001:1442861, “4, 7-Pteridinediamine, 9-phenyl-2-[(phenylmethyl)thio]-,” CAS Registry 343347-55-7 (Jul. 1, 2001).
Chemical Abstracts, vol. 54, No. 10, May 1960, Abstract No. 9933f, C. Wayne Noell and Roland K. Robins, “Potential Purine Antagonists XVII. Synthesis of 2-methyl and 2-methylthio-6, 8-disubstituted purines”, see formula III when R-SMe, R1=C1, R2=OH.
Cohen et al., “Cytokine function: A study in biologic diversity”, Caplus 125:31527 (1996).
Cowley et al., “Preparation of 1-(3-phenyloxypropyl)piperdine derivatives as opioid receptor ligands”, Caplus 138:39189 (2002).
Faubl, “Preparation of 5-Tetrazolyl Groups from Carboxylic Acids. A Sequence Amenable to Sensitive Substrates”,Tetrahedron Letters6:491-494 (1979).
Finke et al., “Preparation of piperidinylmethylcyclopentanes as modulators of CCR-5 and/or CCR-3 chemokine receptors”, Caplus 134:56576 (2000) CAS Listing, 77 answers.
Fukuda et al., “Preparation of benzotriazole derivatives as cardiovascular agents and antipsychotics”, Caplus 123:340149 (1995).
Gavezzotti, “Are Crystal Structures Predictable?”,Acc. Chem. Res. 27:309-314 (1994).
Gewald et al., “New Synthesis of Substituted 4-Amino-quinazolines and Their Heteroanaloga”,J. prakt. Chem. 338:206-213 (1996).
Grant, “University of Minnesota—Twin Cities Campus College of Pharmacy, Annual Report”, [online] 1999, [retrieve on Feb. 13, 2003]. Retrieved from the internet, http://www.msi.umn.edu/general/Reports/ar99/departments/pharmacy.html.
Grohe et al., “Cycloacylation of Enamines, I. —Synthesis of 2-Thiazolone Derivatives”,Liebigs Ann. Chem. 1018-1024 (1973).
Lee et al., “Characterization of Two High Affinity Human Interleukin-8 Receptors”,J. Biol. Chem. 267:16283-16287 (1992).
McNaught et al., “IUPAC Compendium of Chemical Terminology, 2ndEd” (1997).
Merritt et al., “Use of fluo-3 to measure cytosolic Ca2+in platelets and neutrophils: Loading cells with the dye, calibration of traces, measurements in the presence of plasma, and buffering of cytosolic Ca2+”,Biochem. J. 269:513-519 (1990).
Murdoch and Finn, “Chemokine receptors and their role in inflammation and infectious diseases”,Blood95:3032 (3043 (2000).
Na

Affiliated with

Also associated with

Rating

Pteridine compounds for the treatment of psoriasis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pteridine compounds for the treatment of psoriasis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pteridine compounds for the treatment of psoriasis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4105950